Literature DB >> 17015038

Mechanism of HBD-3 deficiency in atopic dermatitis.

Michael D Howell1, Mark Boguniewicz, Saveria Pastore, Natalija Novak, Thomas Bieber, Giampiero Girolomoni, Donald Y M Leung.   

Abstract

Extrinsic atopic dermatitis (EAD) and intrinsic atopic dermatitis (IAD) patients suffer from recurrent bacterial and viral infections. In this study, we demonstrate significantly decreased expression of human beta defensin (HBD)-3, a potent antimicrobial peptide (AMP), in lesional skin of both IAD (p<0.01) and EAD patients (p<0.01), as compared to psoriasis patients. Using primary keratinocytes from EAD and IAD patients, we determined that the deficiency in HBD-3 expression is an acquired rather than a constitutive defect. Furthermore, we demonstrate the down-regulatory effect of IL-4, IL-10, and IL-13 - which are over-expressed in the skin of AD patients - on HBD-3 expression in keratinocytes. Additionally, treatment of EAD skin explants with antibodies against IL-4, IL-10, and IL-13 augmented the expression of HBD-3. These studies suggest that neutralizing the Th2 cytokine milieu in AD skin may augment the innate immune response against bacterial and viral pathogens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015038     DOI: 10.1016/j.clim.2006.08.008

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  50 in total

1.  Innate barriers against infection and associated disorders.

Authors:  Richard L Gallo; Victor Nizet
Journal:  Drug Discov Today Dis Mech       Date:  2008-06-01

2.  Comorbidity in Atopic Dermatitis.

Authors:  Eric L Simpson
Journal:  Curr Dermatol Rep       Date:  2012-03-01

Review 3.  Cholinergic regulation of keratinocyte innate immunity and permeability barrier integrity: new perspectives in epidermal immunity and disease.

Authors:  Brenda J Curtis; Katherine A Radek
Journal:  J Invest Dermatol       Date:  2011-09-15       Impact factor: 8.551

4.  The effect of calcipotriol on the expression of human beta defensin-2 and LL-37 in cultured human keratinocytes.

Authors:  Beom Joon Kim; Yong Kwan Rho; Hye In Lee; Mi Sook Jeong; Kapsok Li; Seong Jun Seo; Myeung Nam Kim; Chang Kwun Hong
Journal:  Clin Dev Immunol       Date:  2010-02-22

Review 5.  Atopic dermatitis in children: clinical features, pathophysiology, and treatment.

Authors:  Jonathan J Lyons; Joshua D Milner; Kelly D Stone
Journal:  Immunol Allergy Clin North Am       Date:  2014-11-21       Impact factor: 3.479

6.  Host-microbial dialogues in atopic dermatitis.

Authors:  Tetsuro Kobayashi; Keisuke Nagao
Journal:  Int Immunol       Date:  2019-07-13       Impact factor: 4.823

7.  Esophageal human β-defensin expression in eosinophilic esophagitis.

Authors:  Shauna Schroeder; Zachary D Robinson; Joanne C Masterson; Lindsay Hosford; Wendy Moore; Zhaoxing Pan; Rachel Harris; Rhonda F Souza; Stuart Jon Spechler; Sophie A Fillon; Glenn T Furuta
Journal:  Pediatr Res       Date:  2013-02-05       Impact factor: 3.756

8.  Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis.

Authors:  Emma Guttman-Yassky; Michelle A Lowes; Judilyn Fuentes-Duculan; Lisa C Zaba; Irma Cardinale; Kristine E Nograles; Artemis Khatcherian; Inna Novitskaya; John A Carucci; Reuven Bergman; James G Krueger
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

9.  Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin.

Authors:  Patrick A M Jansen; Diana Rodijk-Olthuis; Edward J Hollox; Marijke Kamsteeg; Geuranne S Tjabringa; Gys J de Jongh; Ivonne M J J van Vlijmen-Willems; Judith G M Bergboer; Michelle M van Rossum; Elke M G J de Jong; Martin den Heijer; Andrea W M Evers; Mieke Bergers; John A L Armour; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

10.  Bcl-3 acts as an innate immune modulator by controlling antimicrobial responses in keratinocytes.

Authors:  Amanda S Büchau; Daniel T MacLeod; Shin Morizane; Paul F Kotol; Tissa Hata; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2009-03-12       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.